GPT and metabolic dysfunction-associated steatohepatitis: In a 12-week Phase 2a study FASCINATE-1, denifanstat reduced liver fat content in subjects with NASH and improved serum markers of fibrosis and inflammation, including ALT, PRO-C3 and CK-1824.